Free tool
FAERS Monitor: Increlex
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 021839 or its brand name (Increlex, Mecasermin Recombinant). Reports on generic versions are filed under their own applications.
Reports
812
Serious
433
53% of reports
Hospitalization
221
Death reported
24
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use133
- headache67
- hypoglycaemia62
- vomiting44
- injection site pain41
- drug dose omission40
- blood glucose decreased36
- pyrexia36
- tonsillar hypertrophy36
- fatigue34
- product dose omission issue30
- decreased appetite27
- injection site pruritus25
- injection site erythema24
- drug ineffective22
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 2 |
| 2007 | 29 |
| 2008 | 52 |
| 2009 | 16 |
| 2010 | 41 |
| 2011 | 65 |
| 2012 | 49 |
| 2013 | 23 |
| 2014 | 28 |
| 2015 | 21 |
| 2016 | 19 |
| 2017 | 212 |
| 2018 | 60 |
| 2019 | 43 |
| 2020 | 25 |
| 2021 | 21 |
| 2022 | 25 |
| 2023 | 11 |
| 2024 | 12 |
| 2025 | 45 |
| 2026 | 13 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,347 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| tonsillar hypertrophySignal | 36 | 567.1 | 410.6 | 19,359 |
| hypoglycaemiaSignal | 62 | 33.2 | 26.1 | 1,903 |
| blood glucose decreasedSignal | 36 | 19.4 | 14.1 | 612 |
| injection site pruritusSignal | 25 | 9.7 | 6.6 | 186 |
| drug dose omissionSignal | 40 | 6.3 | 4.6 | 173 |
| injection site erythemaSignal | 24 | 5.0 | 3.4 | 74 |
| off label useSignal | 133 | 3.9 | 3.4 | 301 |
| injection site painSignal | 41 | 3.5 | 2.6 | 70 |
| decreased appetiteSignal | 27 | 3.0 | 2.1 | 35 |
| headacheSignal | 67 | 2.8 | 2.2 | 76 |
| pyrexiaSignal | 36 | 2.7 | 2.0 | 37 |
| product dose omission issueSignal | 30 | 2.6 | 1.9 | 29 |
| vomitingSignal | 44 | 2.4 | 1.8 | 36 |
| fatigue | 34 | 1.1 | 0.8 | 0 |
| drug ineffective | 22 | 0.4 | 0.3 | 17 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.